Literature DB >> 21424106

Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization.

Kazuhiro Suzuki1, Ruowen Sun, Makoto Origuchi, Masahiko Kanehira, Takenori Takahata, Jugoh Itoh, Akihiro Umezawa, Hiroshi Kijima, Shinsaku Fukuda, Yasuo Saijo.   

Abstract

Mesenchymal stromal cells (MSCs), also called mesenchymal stem cells, migrate and function as stromal cells in tumor tissues. The effects of MSCs on tumor growth are controversial. In this study, we showed that MSCs increase proliferation of tumor cells in vitro and promote tumor growth in vivo. We also further analyzed the mechanisms that underlie these effects. For use in in vitro and in vivo experiments, we established a bone marrow-derived mesenchymal stromal cell line from cells isolated in C57BL/6 mice. Effects of murine MSCs on tumor cell proliferation in vitro were analyzed in a coculture model with B16-LacZ cells. Both coculture with MSCs and treatment with MSC-conditioned media led to enhanced growth of B16-LacZ cells, although the magnitude of growth stimulation in cocultured cells was greater than that of cells treated with conditioned media. Co-injection of B16-LacZ cells and MSCs into syngeneic mice led to increased tumor size compared with injection of B16-LacZ cells alone. Identical experiments using Lewis lung carcinoma (LLC) cells instead of B16-LacZ cells yielded similar results. Consistent with a role for neovascularization in MSC-mediated tumor growth, tumor vessel area was greater in tumors resulting from co-injection of B16-LacZ cells or LLCs with MSCs than in tumors induced by injection of cancer cells alone. Co-injected MSCs directly supported the tumor vasculature by localizing close to vascular walls and by expressing an endothelial marker. Furthermore, secretion of leukemia inhibitory factor, macrophage colony-stimulating factor, macrophage inflammatory protein-2 and vascular endothelial growth factor was increased in cocultures of MSCs and B16-LacZ cells compared with B16-LacZ cells alone. Together, these results indicate that MSCs promote tumor growth both in vitro and in vivo and suggest that tumor promotion in vivo may be attributable in part to enhanced angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21424106      PMCID: PMC3146617          DOI: 10.2119/molmed.2010.00157

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  38 in total

Review 1.  Mesenchymal stem cell homing: the devil is in the details.

Authors:  Jeffrey M Karp; Grace Sock Leng Teo
Journal:  Cell Stem Cell       Date:  2009-03-06       Impact factor: 24.633

2.  The pro-inflammatory peptide LL-37 promotes ovarian tumor progression through recruitment of multipotent mesenchymal stromal cells.

Authors:  Seth B Coffelt; Frank C Marini; Keri Watson; Kevin J Zwezdaryk; Jennifer L Dembinski; Heather L LaMarca; Suzanne L Tomchuck; Kerstin Honer zu Bentrup; Elizabeth S Danka; Sarah L Henkle; Aline B Scandurro
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-20       Impact factor: 11.205

3.  Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas.

Authors:  Daniel Bexell; Salina Gunnarsson; Ariane Tormin; Anna Darabi; David Gisselsson; Laurent Roybon; Stefan Scheding; Johan Bengzon
Journal:  Mol Ther       Date:  2008-11-04       Impact factor: 11.454

4.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer.

Authors:  Janna Paulsson; Tobias Sjöblom; Patrick Micke; Fredrik Pontén; Göran Landberg; Carl-Henrik Heldin; Jonas Bergh; Donal J Brennan; Karin Jirström; Arne Ostman
Journal:  Am J Pathol       Date:  2009-06-04       Impact factor: 4.307

5.  Cytokine modulation of TLR expression and activation in mesenchymal stromal cells leads to a proinflammatory phenotype.

Authors:  Raphaëlle Romieu-Mourez; Moïra François; Marie-Noëlle Boivin; Manaf Bouchentouf; David E Spaner; Jacques Galipeau
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

6.  Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells.

Authors:  Keishi Otsu; Shonit Das; Sandra D Houser; Sadiqa K Quadri; Sunita Bhattacharya; Jahar Bhattacharya
Journal:  Blood       Date:  2008-11-25       Impact factor: 22.113

7.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells.

Authors:  Pravin J Mishra; Prasun J Mishra; Rita Humeniuk; Daniel J Medina; Gabriela Alexe; Jill P Mesirov; Sridhar Ganesan; John W Glod; Debabrata Banerjee
Journal:  Cancer Res       Date:  2008-06-01       Impact factor: 12.701

8.  Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis.

Authors:  Sunhwa Kim; Hiroyuki Takahashi; Wan-Wan Lin; Pascal Descargues; Sergei Grivennikov; Youngjun Kim; Jun-Li Luo; Michael Karin
Journal:  Nature       Date:  2009-01-01       Impact factor: 49.962

9.  Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression.

Authors:  Erika L Spaeth; Jennifer L Dembinski; A Kate Sasser; Keri Watson; Ann Klopp; Brett Hall; Michael Andreeff; Frank Marini
Journal:  PLoS One       Date:  2009-04-07       Impact factor: 3.240

10.  VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma.

Authors:  B M Beckermann; G Kallifatidis; A Groth; D Frommhold; A Apel; J Mattern; A V Salnikov; G Moldenhauer; W Wagner; A Diehlmann; R Saffrich; M Schubert; A D Ho; N Giese; M W Büchler; H Friess; P Büchler; I Herr
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

View more
  85 in total

1.  Inhibitory effect and mechanism of mesenchymal stem cells on melanoma cells.

Authors:  J Zhang; L Hou; D Zhao; M Pan; Z Wang; H Hu; J He
Journal:  Clin Transl Oncol       Date:  2017-07-21       Impact factor: 3.405

2.  Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review.

Authors:  Ioannis Christodoulou; Maria Goulielmaki; Marina Devetzi; Mihalis Panagiotidis; Georgios Koliakos; Vassilis Zoumpourlis
Journal:  Stem Cell Res Ther       Date:  2018-12-07       Impact factor: 6.832

3.  Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells.

Authors:  Scott A Bergfeld; Laurence Blavier; Yves A DeClerck
Journal:  Mol Cancer Ther       Date:  2014-02-06       Impact factor: 6.261

Review 4.  Mesenchymal stem cells in the tumor microenvironment.

Authors:  Jian Guan; Jie Chen
Journal:  Biomed Rep       Date:  2013-05-10

5.  Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression.

Authors:  Robert M Hughes; Brian W Simons; Hamda Khan; Rebecca Miller; Valentina Kugler; Samantha Torquato; Debebe Theodros; Michael C Haffner; Tamara Lotan; Jessie Huang; Elai Davicioni; Steven S An; Ryan C Riddle; Daniel L J Thorek; Isla P Garraway; Elana J Fertig; John T Isaacs; W Nathaniel Brennen; Ben H Park; Paula J Hurley
Journal:  Cancer Res       Date:  2019-05-23       Impact factor: 12.701

6.  Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway.

Authors:  Dandan Chen; Ping Tang; Linxiang Liu; Fang Wang; Haizhou Xing; Ling Sun; Zhongxing Jiang
Journal:  Cell Cycle       Date:  2018-05-21       Impact factor: 4.534

7.  Zoledronic acid in breast cancer: latest findings and interpretations.

Authors:  Michael Gnant
Journal:  Ther Adv Med Oncol       Date:  2011-11       Impact factor: 8.168

8.  IL-6 originated from breast cancer tissue-derived mesenchymal stromal cells may contribute to carcinogenesis.

Authors:  Özlem Sağlam; Zehra Seda Ünal; Cansu Subaşı; Engin Ulukaya; Erdal Karaöz
Journal:  Tumour Biol       Date:  2015-02-20

9.  MFG-E8 Drives Melanoma Growth by Stimulating Mesenchymal Stromal Cell-Induced Angiogenesis and M2 Polarization of Tumor-Associated Macrophages.

Authors:  Kazuya Yamada; Akihiko Uchiyama; Akihito Uehara; Buddhini Perera; Sachiko Ogino; Yoko Yokoyama; Yuko Takeuchi; Mark C Udey; Osamu Ishikawa; Sei-Ichiro Motegi
Journal:  Cancer Res       Date:  2016-05-17       Impact factor: 12.701

10.  Tumor-driven Molecular Changes in Human Mesenchymal Stromal Cells.

Authors:  Lucia Kucerova; Jakub Zmajkovic; Lenka Toro; Svetlana Skolekova; Lucia Demkova; Miroslava Matuskova
Journal:  Cancer Microenviron       Date:  2014-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.